Abstract 5129
Background
Describe adherence patterns to the medical control processes derived from belonging to a CG situation in a sample of patients in CG situation for hereditary breast and ovarian cancer (CMOH), and its consequences with Psychological Wellbeing.
Methods
Descriptive cross-sectional descriptive study. Participants: Women carriers of high penetrance genes for breast and ovarian cancer (BRCA1 / 2), during the months of July 2012 to May 2014 who continue to control the Hereditary Cancer program of the Català Oncología Institute. 176 women. For the adhesion assessment, 3 asdoca questions were asked, based on recommendations and guidelines, the scale of the psychological well-being (BP) of Ryff was used, validated in the Spanish population.
Results
Regarding breast autoexploration, 58.6% of the patients did not follow the correct follow-up (either by hypervigilance or hypovigilance). Regarding the follow-ups in mammographic controls, 51.4% of the patients do the correct follow-up. When analyzing the relationship between breast self-exploration and the dimensions of psychological well-being, no statistically significant differences were found in any case, the same happens with mammographic controls Regarding the follow-up by MRI, 51.4% of the patients follow the correct one. A relationship is found in the dimension of Autonomy and Purpose in life.
Conclusions
The literature reports that there are well-defined and structured medical treatment protocols that allow monitoring of the carrier patients and that these are understandable to them with the final objective that patients have strategies to manage the situation without uncertainty (Ringwald et al., 2016). One possible explanation is that patients do not fully understand the protocols or that there are other personality variables that are modulating this aspect, such as a passive coping style or a high perception of risk (Den Heijer et al., 2013; Gopie et al., 2012). Conclusions Our population, approximately 50% of patients do not adhere to the proposed follow-up measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melinda Gonzalez Concepcion.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract